Bristol Myers presents results from COLLIGO-HCM trial at ESC Congress

Bristol Myers (BMY) presented results from COLLIGO-HCM in an oral session at the European Society of Cardiology Congress 2025 in Madrid, Spain. The analysis showed that Camzyos was associated with reductions in left ventricular outflow tract obstruction and improvements in symptom burden in a racially diverse population of patients with symptomatic obstructive hypertrophic cardiomyopathy treated in an international, real-world setting. The effectiveness and safety demonstrated in COLLIGO-HCM are consistent with results from randomized, controlled clinical trials and further support the growing body of evidence for Camzyos, the first and only approved cardiac myosin inhibitor, as a standard of care for New York Heart Association class II-III symptomatic oHCM. Results showed that 59.9% of patients achieved 1 NYHA class improvement by week 24. Overall, 86.5% of patients with at least 12 weeks of follow-up and 94.4% of patients with at least 24 weeks of follow-up had an NYHA classification of II or below, including 30.9% who had an NYHA classification of I; these proportions improved consistently through week 96. By week 36, almost all patients achieved mean LVOT gradients of 30 mm Hg at rest, and 76.8% after Valsalva provocation; these proportions remained consistent through week 96. Some patients, 7.2%, initiated Camzyos as monotherapy. Of patients on background medication at baseline, 26.4% discontinued at least one type of therapy, and 5% down-titrated background medication after starting Camzyos. Mean left ventricular ejection fraction following Camzyos initiation remained at or above 61% throughout follow-up; the baseline value was 66%. Temporary interruption of Camzyos due to LVEF 50% occurred in 11 patients and permanent discontinuation due to LVEF 50% occurred in three patients. All patients’ LVEF returned to greater than 50% after permanent discontinuation of Camzyos. Echocardiogram requirements to monitor LVEF are country dependent, including a Risk Evaluation and Mitigation Strategy program in the U.S. The proportion of patients with LVEF 50% aligns with the published safety profile of Camzyos and was consistent across all sites, regardless of echocardiogram monitoring requirements. New-onset atrial fibrillation was recorded in eight patients, which is consistent with previously reported data from other real-world evidence studies as well as the pivotal oHCM clinical trials for Camzyos. Camzyos is a standard of care for the treatment of NYHA class II-III symptomatic oHCM and is included in both the ESC and AHA/ACC clinical guidelines as a recommended option for when symptoms persist after first-line therapy.